

EFFECTIVENESS OF NON-PHARMACOLOGICAL INTERVENTIONS TO IMPROVE COGNITION IN CANCER: A PROTOCOL FOR AN OVERVIEW OF SYSTEMATIC REVIEWS

Darren Haywood PhD^{1,2,3,4*}, Ashley M. Henneghan PhD^{5,6}, Evan Dauer MclinPsych^{1,2}, Sherry Vasani PhD², Oscar Y. Franco-Rocha RN^{5,6}, Helen Wilding BSc², & Nicolas H. Hart PhD^{1,7,8,9,10}

1. Human Performance Research Centre, INSIGHT Research Institute, Faculty of Health, University of Technology Sydney (UTS), Sydney, NSW, Australia.
2. Department of Mental Health, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia.
3. Department of Psychiatry, Melbourne Medical School, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia
4. School of Population Health, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
5. School of Nursing, University of Texas at Austin, Austin, Texas, USA
6. Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA
7. Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia
8. Exercise Medicine Research Institute, School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia
9. Cancer and Palliative Care Outcomes Centre, Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD, Australia
10. Institute for Health Research, University of Notre Dame Australia, Perth, WA, Australia.

Keywords

Cancer; Cognition; cancer-related cognitive impairment; non-pharmacological; intervention; exercise; physical activity; diet; nutrition; Cognitive behavioral therapy; mindfulness; meditation; behavioral therapy; self-management; mind-body; cognitive training; cognitive rehabilitation.

Abstract

Many cancer survivors, including those with a current or previous diagnosis of cancer, experience cancer-related cognitive impairments (CRCI). CRCI can impact their ability to think quickly, clearly, make decisions and perform daily actions. There have been a variety of non-pharmacological interventions developed and trialed with the aim of reducing CRCI or mitigating its impact. The aim of this work is to provide an overall picture of the effectiveness of non-pharmacological interventions to improve cognition in cancer survivors by providing an overview and synthesis of systematic reviews.

Review Title

Effectiveness of Non-Pharmacological Interventions to Improve Cognition in Cancer: An Overview of Systematic Reviews

Background

A significant proportion of cancer survivors, defined as anyone who has had a cancer diagnosis, experience cognitive impairments that can impact their ability to think quickly, clearly, make decisions and perform daily actions [1-3]. This is commonly called cancer-related cognitive impairment (CRCI) [1]. It is largely believed that cancer, cancer treatments, and psychosocial factors may all contribute to the development and maintenance of CRCI [4]. Cognitive impairment is also generally related to a variety of negative physical and psychological outcomes across populations [5-10], and cancer survivors are at a heightened risk of experiencing these outcomes, such as psychopathology [11]. To reduce CRCI and minimise its impact, a wide variety of non-pharmacological interventions have been trialed across human and animal cancer survivor populations including exercise, cognitive behavioural therapy, cognitive training, dietary, and mindfulness interventions [4]. There have now been several systematic reviews published, both broader and narrower in scope, that have examined the effectiveness of various non-pharmacological interventions aimed at improving cognition in cancer survivors of various types. To provide an overall picture of the effectiveness of non-pharmacological interventions to improve cognition in cancer survivors an overview and synthesis of these systematic reviews is required. This overview may inform clinical guidelines and educational responses, as well as point toward the most promising interventions and uncover gaps in the current systematic review literature.

Objective

- To provide a comprehensive overview of systematic reviews examining the effectiveness of any non-pharmacological interventions aimed at improving cognition in cancer populations.

Anticipated or Actual Start Date

12/03/24

Anticipated Completion Date

15/08/24

Named Contact

Dr Darren Haywood, darren.haywood@uts.edu.au

Organizational Affiliation of the Review.

University of Technology Sydney

Review Team Members and their Organizational Affiliations.

PI: Name: Darren Haywood, PhD, BPsych(Hons), Dip. Fit
Postdoctoral Research Fellow (Cancer Survivorship)
Human Performance Research Centre
Email: Darren.haywood@uts.edu.au

Co-PI: Name: Nicolas H. Hart, PhD AES CSCS ESSAF, Associate Professor
NHMRC Investigator Fellow (Cancer Survivorship)
Program Director (Clinical Exercise Physiology)
Human Performance Research Centre
University of Technology Sydney (UTS)
Email: nicolas.hart@uts.edu.au

Investigator: Name: Ashley M. Henneghan, PhD, RN, Associate Professor
School of Nursing
University of Texas at Austin
Email: ahenneghan@nursing.utexas.edu

Investigator: Name: Evan Dauer, MClInPsych, BSc(Hons)
Research Fellow
Human Performance Research Centre
Email: evan.dauer@uts.edu.au

Investigator: Name: Sherry Vasan, PhD, BSc(Hons)
Research Fellow
Human Performance Research Centre
Email: sherry.vasan@svha.org.au

Investigator: Name: Oscar Y. Franco-Rocha, M.Ed., RN, PhD Student
School of Nursing
University of Texas at Austin
Email: oscar.franco-rocha@austin.utexas.edu

Funding sources/sponsors.

There is no financial support for this research.

Investigator: Name: Helen Wilding
Senior Research Librarian
St. Vincent's Hospital Melbourne
Email: helen.wilding@svha.org.au

Funding sources/sponsors.

There is no financial support for this research.

Conflicts of interest.

None.

Collaborators.

None.

Review Question

What is the effectiveness of non-pharmacological interventions for improving cognition in cancer populations?

Searches

Medline ALL (Ovid), Embase (Ovid), Emcare (Ovid), APA PsycINFO (Ovid), CINAHL (EBSCOhost), Cochrane Library (Wiley). Search date 12/03/24.

No age restrictions. To identify additional potentially relevant studies the reference list of included systematic reviews will be hand-searched.

Exact searches are presented below for each database.

Ovid MEDLINE(R) ALL 1946 to March 12, 2024

1. exp Neoplasms/ or Cancer Survivors/ or Cancer Care Facilities/ or Oncology Service, Hospital/ or exp Medical Oncology/ or Oncology Nursing/ or Cancer Pain/
2. (cancer* or carcinoma* or glioblastoma* or leuk?emia* or lymphoma* or malignan* or neoplasm* or tumo?r or tumo?rs or oncolog*).ti,ab,kf.
3. 1 or 2
4. cognition/ or awareness/ or cognitive reserve/ or comprehension/ or metacognition/ or processing speed/
5. cognition disorders/ or cognitive dysfunction/ or chemotherapy-related cognitive impairment/ or postoperative cognitive complications/
6. attention/ or executive function/
7. memory/ or memory, episodic/ or memory, long-term/ or memory, short-term/ or mental recall/
8. Mental Processes/ or Neurobehavioral Manifestations/ or exp Neuropsychological Tests/ or Problem Solving/
9. thinking/ or concept formation/ or judgment/
10. (chemobrain or chemo-brain or chemofog or chemo-fog or cognit* or concept formation or executive function* or metacognit* or memory or mental process*).ti,ab,kf.
11. (neurobehavioral manifest* or neurocognit* or neuropsychological test* or processing speed).ti,ab,kf.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. meta-analysis/ or "systematic review"/ or Systematic Reviews as Topic/
14. ((system* or literature) adj2 (review* or search)).ti,ab,kf.
15. (cochrane review or meta-analysis or meta-synthesis or narrative review* or quantitative review* or systematic overview* or prisma or medline or pubmed or embase).ti,ab,kf.
16. (meta analysis or "systematic review").pt.

17. 13 or 14 or 15 or 16
18. 3 and 12 and 17
19. (case reports or comment or editorial or letter or news).pt.
20. 18 not 19

Embase 1974 to 2024 March 12 (Ovid)

1. exp *neoplasm/ or *cancer survivor/ or *cancer patient/ or exp *cancer survival/ or exp *cancer therapy/ or *cancer center/ or exp *oncology/ or *oncology ward/
2. (cancer* or carcinoma* or glioblastoma* or leuk?emia* or lymphoma* or malignan* or neoplasm* or tumo?r or tumo?rs or oncolog*).ti,ab,kf.
3. 3., 1 or 2
4. *chemotherapy-related cognitive impairment/ or *cognitive defect/ or *mild cognitive impairment/ or *postoperative cognitive dysfunction/
5. *cognition/ or *attention/ or *cognitive reserve/ or *executive function/ or *memory/ or *metacognition/ or *processing speed/ or *thinking/ or exp *neuropsychological assessment/
6. (chemobrain or chemo-brain or chemofog or chemo-fog or cognit* or concept formation or executive function* or metacognit* or memory or mental process*).ti,ab,kf.
7. (neurobehavioral manifest* or neurocognit* or neuropsychological test* or processing speed).ti,ab,kf.
8. 4 or 5 or 6 or 7
9. "systematic review"/ or "systematic review (topic)"/ or meta analysis/ or "meta analysis (topic)"/
10. ((system* or literature) adj2 (review* or search)).ti,ab,kf.
11. (cochrane review or meta-analysis or meta-synthesis or narrative review* or quantitative review* or systematic overview* or prisma or medline or pubmed or embase).ti,ab,kf.
12. 9 or 10 or 11
13. 3 and 8 and 12
14. (book or chapter or conference or conference abstract or conference paper or "conference review" or editorial or letter or note).pt.
15. case report.ti.
16. 14 or 15
17. 13 not 16

Ovid Emcare 1995 to 2024 Week 10

1. exp *neoplasm/ or *cancer survivor/ or *cancer patient/ or exp *cancer survival/ or exp *cancer therapy/ or *cancer center/ or exp *oncology/ or *oncology ward/
2. (cancer* or carcinoma* or glioblastoma* or leuk?emia* or lymphoma* or malignan* or neoplasm* or tumo?r or tumo?rs or oncolog*).ti,ab,kf.
3. 1 or 2
4. *chemotherapy-related cognitive impairment/ or *cognitive defect/ or *mild cognitive impairment/ or *postoperative cognitive dysfunction/
5. *cognition/ or *attention/ or *cognitive reserve/ or *executive function/ or *memory/ or *metacognition/ or *processing speed/ or *thinking/ or exp neuropsychological test/
6. (chemobrain or chemo-brain or chemofog or chemo-fog or cognit* or concept formation or executive function* or metacognit* or memory or mental process*).ti,ab,kf.
7. (neurobehavioral manifest* or neurocognit* or neuropsychological test* or processing speed).ti,ab,kf.
8. 4 or 5 or 6 or 7
9. "systematic review"/ or "systematic review (topic)"/ or meta analysis/ or "meta analysis (topic)"/

10. ((system* or literature) adj2 (review* or search)).ti,ab,kf.
11. (cochrane review or meta-analysis or meta-synthesis or narrative review* or quantitative review* or systematic overview* or prisma or medline or pubmed or embase).ti,ab,kf.
12. 9 or 10 or 11
13. 3 and 8 and 12
14. (book or chapter or conference or conference abstract or conference paper or "conference review" or editorial or letter or note).pt.
15. case report.ti.
16. 14 or 15
17. 13 not 16

APA PsycInfo 1806 to March Week 2 2024 (Ovid)

1. exp neoplasms/ or oncology/
2. (cancer* or carcinoma* or glioblastoma* or leuk?emia* or lymphoma* or malignan* or neoplasm* or tumo?r or tumo?rs or oncolog*).ti,ab.
3. 1 or 2
4. cognitive processes/ or exp awareness/ or exp cognition/ or exp cognitive ability/ or cognitive processing speed/ or cognitive reserve/ or exp cognitive strategies/ or concentration/ or exp concept formation/ or exp executive function/ or exp judgment/ or metacognition/ or exp problem solving/ or exp thinking/ or exp cognitive assessment/
5. cognitive impairment/ or mild cognitive impairment/ or neurocognitive disorders/ or memory/
6. (chemobrain or chemo-brain or chemofog or chemo-fog or cognit* or concept formation or executive function* or metacognit* or memory or mental process*).ti,ab.
7. (neurobehavioral manifest* or neurocognit* or neuropsychological test* or processing speed).ti,ab.
8. 4 or 5 or 6 or 7
9. "systematic review"/ or "literature review"/ or meta analysis/
10. ((system* or literature) adj2 (review* or search)).ti,ab.
11. (cochrane review or meta-analysis or meta-synthesis or narrative review* or quantitative review* or systematic overview* or prisma or medline or pubmed or embase).ti,ab.
12. 9 or 10 or 11
13. 3 and 8 and 12

CINAHL (EBSCOhost)

- S1. (MH "Cancer Survivors") OR (MH "Cancer Patients") OR (MH "Cancer Fatigue") OR (MH "Cancer Pain") OR (MH "Chemotherapy, Cancer+") OR (MH "Rehabilitation, Cancer")
- S2. (MH "Neoplasms+") OR (MH "Oncology+") OR (MH "Oncology Nursing+")
- S3. cancer* OR carcinoma* OR glioblastoma* OR leuk#emia* OR lymphoma* OR malignan* OR neoplasm* OR tumo#r OR tumo#rs OR oncolog*
- S4. S1 OR S2 OR S3
- S5. (MH "Cognition Disorders+") OR (MH "Chemotherapy-Related Cognitive Impairment") OR (MH "Mild Cognitive Impairment")
- S6. (MH "Cognition") OR (MH "Processing Speed") OR (MH "Executive Function") OR (MH "Mental Processes") OR (MH "Thinking")
- S7. (MH "Problem Solving") OR (MH "Memory") OR (MH "Neuropsychological Tests+")
- S8. chemobrain OR chemo-brain OR chemofog OR chemo-fog OR cognit* OR "concept formation" OR "executive function*" OR metacognit* OR memory OR "mental process"
- S9. "neurobehavioral manifest*" OR neurocognit* OR "neuropsychological test*" OR "processing speed"

- S10. S5 OR S6 OR S7 OR S8 OR S9
- S11. (MH "Literature Review+") OR (MH "Systematic Review") OR (MH "Scoping Review") OR (MH "Meta Analysis")
- S12. (system* OR literature) N2 (review* OR search)
- S13. "cochrane review" OR meta-analysis OR meta-synthesis OR "narrative review*" OR "quantitative review*" OR "systematic overview*" OR prisma OR medline OR pubmed OR embase
- S14. S11 OR S12 OR S13
- S15. S4 AND S10 AND S14

Cochrane Library (Wiley)

- 1. [mh Neoplasms] OR [mh ^"Cancer Survivors"] OR [mh ^"Cancer Care Facilities"] OR [mh ^"Oncology Service, Hospital"] OR [mh "Medical Oncology"] OR [mh ^"Oncology Nursing"] OR [mh ^"Cancer Pain"]
- 2. cancer*:ti,ab OR carcinoma*:ti,ab OR glioblastoma*:ti,ab OR leuk?emia*:ti,ab OR lymphoma*:ti,ab OR malignan*:ti,ab OR neoplasm*:ti,ab OR tumo?:ti,ab OR tumo?rs:ti,ab OR oncolog*:ti,ab
- 3. #1 OR #2
- 4. [mh ^cognition] OR [mh ^awareness] OR [mh ^"cognitive reserve"] OR [mh ^comprehension] OR [mh ^metacognition] OR [mh ^"processing speed"]
- 5. [mh ^"cognition disorders"] OR [mh ^"cognitive dysfunction"] OR [mh ^"chemotherapy-related cognitive impairment"] OR [mh ^"postoperative cognitive complications"]
- 6. [mh ^attention] OR [mh ^"executive function"]
- 7. [mh ^memory] OR [mh ^"memory, episodic"] OR [mh ^"memory, long-term"] OR [mh ^"memory, short-term"] OR [mh ^"mental recall"]
- 8. [mh ^"Mental Processes"] OR [mh ^"Neurobehavioral Manifestations"] OR [mh "Neuropsychological Tests"] OR [mh ^"Problem Solving"]
- 9. [mh ^thinking] OR [mh ^"concept formation"] OR [mh ^judgment]
- 10. chemobrain:ti,ab OR chemo-brain:ti,ab OR chemofog:ti,ab OR chemo-fog:ti,ab OR cognit*:ti,ab OR "concept formation":ti,ab OR ("executive" NEXT function*):ti,ab OR metacognit*:ti,ab OR memory:ti,ab OR ("mental" NEXT process*):ti,ab
- 11. ("neurobehavioral" NEXT manifest*):ti,ab OR neurocognit*:ti,ab OR ("neuropsychological" NEXT test*):ti,ab OR "processing speed":ti,ab
- 12. #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
- 13. (system*:ti,ab OR literature:ti,ab) NEAR/2 (review*:ti,ab OR search:ti,ab)
- 14. "cochrane review":ti,ab OR meta-analysis:ti,ab OR meta-synthesis:ti,ab OR ("narrative" NEXT review*):ti,ab OR ("quantitative" NEXT review*):ti,ab OR ("systematic" NEXT overview*):ti,ab OR prisma:ti,ab OR medline:ti,ab OR pubmed:ti,ab OR embase:ti,ab
- 15. MeSH descriptor: [Systematic Review] explode all trees
- 16. #13 OR #14 OR #15
- 17. #3 AND #12 AND #16

PICO

- Participants/Population.

Populations who have had a cancer diagnosis, either current or previous. Any stage of the cancer journey. All types of cancer. All types of treatments. All ages. All genders/sexes. Humans or animals.

- Intervention(s), Exposure(s).

Non-pharmacological interventions aimed to improve cognition.

- Comparator(s)/Control.

Must include a within or between group comparison. All comparisons are included (i.e., to a control group, pre-post, etc).

- Outcome.

Cognitive functioning (subjective and/or objective)

Condition or Domain Being Studied.

Cognition, Cancer, non-pharmacological interventions.

Types of Study to be Included.

Systematic reviews reporting the effectiveness of non-pharmacological interventions to improve cognition in cancer populations.

‘Systematic review’ was defined using the PRISMA-P statement definition of a SR: (A) had an explicit aim; (B) used a systematic search strategy and selection of studies; and (C) systematically synthesized data using narrative synthesis and/or meta-analysis. Unpublished work, abstracts, letters, and conference proceedings were not included.

Exclusion Criteria

- Systematic reviews only including studies with pharmacological interventions (including supplements available over the counter) aimed at improving cognition.
- Systematic reviews that do not report on subjective or objective measures of cognition.
- Non-systematic reviews.

Inclusion Criteria

- Systematic reviews examining the effectiveness of any non-pharmacological interventions aimed at improving cognition in cancer populations.
- Human or animal systematic reviews.
- Have been diagnosed with any type of cancer (current or previous), any stage of cancer encompassing the entire cancer trajectory.
- All ages of participants included.
- Systematic reviews that include Subjective and/or objective measures of cognition
- Systematic reviews that include any comparisons to establish intervention effectiveness (i.e., pre-post, control group, etc.)
- Quality of Life (QoL) and other wellbeing systematic reviews in which at least 50% of included primary studies have a cognitive outcome measure.
- Multiple population reviews where cancer is separately analyzed/synthesized and at least 50% of included primary cancer studies have a cognitive outcome measure.

Data Extraction (Selection and Coding)

Study selection and data extraction will follow the Overview of Reviews in Cochrane Handbook for Systematic Reviews of Interventions guidelines [12] and will be reported per PRISMA 2020 statement [13]. The results will be imported to Covidence to remove duplicates and screening. Two reviewers will independently screen the studies in two stages: (1) title/abstract and (2) full texts. Disagreement will be resolved by a third reviewer.

Study characteristics to be extracted will include publication year, title, authors, journal, review type, country, interventions included, length of intervention(s), human or animal, cancer types, cancer treatments, cancer stage(s), comparison type(s), cognitive measures included, QoL and patient reported outcome measure(s) (PROMs) included, effectiveness in improving cognition, effectiveness in improving QoL and patient reported outcomes (PROs).

Risk of Bias (Quality) Assessment

Two investigators will independently conduct a systematic review quality assessment using the Assessment of Multiple SRs (AMSTAR) 2 Checklist, a 16-question tool that evaluates each item as “yes” or “no” and yields a final overall rating of “high,” “moderate,” “low,” or “critically low” quality. Study quality disagreements were managed by consensus between authors and resolved by discussion with a third author if necessary.

Data Synthesis and Analysis

- Narrative Synthesis.
- Corrected Covered Area (CCA) will be calculated to determine the extent to which primary studies overlap in the included SRs.

Analysis of Subgroups or Subsets.

- Types of non-pharmacological interventions included within the systematic reviews will be grouped (i.e., exercise, cognitive training, cognitive behavioural therapy, etc). The results will be narratively synthesised both within and between these groups.

Strategy for Data Synthesis

- Data synthesis will take place using a narrative synthesis approach. No additional re-analysis of outcome data was conducted. Synthesis will be conducted both across intervention types and within intervention types.

Type and Method of Review

Overview of Systematic Reviews “umbrella review”

Health Area of the Review

Cancer and oncology

Language

English

Country

Australia; United States and America.

Ethical Considerations

Not required.

Dissemination Plans

The results will be published in a peer-reviewed journal and presented at academic conferences.

References:

1. Binarelli, G., et al., *Cancer-related cognitive impairment: current perspectives on the management of cognitive changes following cancer treatment*. Expert Review of Neurotherapeutics, 2023. **23**(3): p. 249-268.
2. Haywood, D., et al., *Oncology healthcare professionals' perceptions and experiences of chemobrain in cancer survivors and persons undergoing cancer treatment*. General hospital psychiatry, 2023: p. S0163-8343.
3. Haywood, D., et al., "Is My Brain Ever Going to Work Fully Again?": Challenges and Needs of Cancer Survivors with Persistent Cancer-Related Cognitive Impairment. *Cancers*, 2023. **15**(22): p. 5331.
4. Mayo, S.J., et al., *Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group*. Supportive Care in Cancer, 2021. **29**: p. 2821-2840.
5. Haywood, D., et al., *What Accounts for the Factors of Psychopathology? An Investigation of the Neurocognitive Correlates of Internalising, Externalising, and the p-Factor*. Brain Sciences, 2022.
6. Haywood, D., et al., *Neurocognitive artificial neural network models are superior to linear models at accounting for dimensional psychopathology*. Brain Sciences, 2022. **12**(8): p. 1060.
7. Haywood, D., et al., *Going "Up" to Move Forward: S-1 Bifactor Models and the Study of Neurocognitive Abilities in Psychopathology*. International Journal of Environmental Research and Public Health, 2021. **18**(14): p. 7413.
8. Haywood, D. and F.D. Baughman, *Multidimensionality in Executive Function Profiles in Schizophrenia: A Computational Approach Using the Wisconsin Card Sorting Task*. Computational Brain & Behavior, 2021: p. 1-14.
9. Haywood, D., et al., *Psychopathology and Neurocognition in the Era of the p-Factor: The Current Landscape and the Road Forward*. Psychiatry International, 2021. **2**(3): p. 233-249.
10. John, A.P., T. Mya, and D. Haywood, *Cognitive deficits among people with schizophrenia and prediabetes or diabetes*. Acta Psychiatrica Scandinavica, 2024. **149**(1): p. 65-76.
11. Haywood, D., et al., *Is it time to discard the diagnostic and Statistical Manual of mental disorders (DSM) in psycho-oncology?* 2024, Cancer Letters. p. 216818.
12. Pollock, M., *Overviews of reviews*, in J.T. Higgins, J, Editor. *Cochrane handbook for systematic reviews of interventions*. 2019: Cochrane.
13. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews*. International journal of surgery, 2021. **88**: p. 105906.